Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 138-142 , April 2009

Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis

  • Alawi A. Alsheikh-Ali, MD

      Affiliations

    • Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Box #80, Boston, MA 02111USA
    • Molecular Cardiology Research Institute, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Boston, MA 02111USA
    • ,
  • Richard H. Karas, MD, PhD

      Affiliations

    • Molecular Cardiology Research Institute, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Boston, MA 02111USA
    • Corresponding Author InformationCorresponding author.

Received 13 November 2008 ,Accepted 8 February 2009.

References 

  1. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356
  2. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357–1366
  3. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443
  4. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409–418
  5. Alsheikh-Ali AA, Abourjaily HM, Karas RH. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol. 2002;89:1308–1310
  6. Abourjaily HM, Alsheikh-Ali AA, Karas RH. Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin. Am J Cardiol. 2003;91:999–1002
  7. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. Am J Cardiol. 2004;93:1417–1418
  8. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. 2004;94:935–938
  9. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111:3051–3057
  10. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol. 2005;8:95–97
  11. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol. 2007;99:379–381
  12. Holoshitz N, Alsheikh-Ali AA, Karas RH. Relative safety of gemfibrozil and fenofibrate in the absence of conocmitant cerivastatin use. Am J Cardiol. 2008;101:95–97
  13. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992;86:1046–1060
  14. Alsheikh-Ali AA, Trikalinos TT, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol and risk of cancer. J Am Coll Cardiol. 2008;52:1141–1147
  15. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716–723
  16. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  17. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80
  18. Zetia (ezetimibe) package insert. North Wales, PA, Merck/Schering-Plough Pharmaceuticals, 2007.
  19. Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288:1588
  20. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Advances in inflammation research. New York, NY: Raven Press; 1984;p. 1–7
  21. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24(6):743–749
  22. Rossi AC, Knapp DE, Anello C, et al. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. JAMA. 1983;249:2226–2228
  23. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–540

PII: S1933-2874(09)00080-4

doi: 10.1016/j.jacl.2009.02.005

Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 138-142 , April 2009

Article Tools

* Image Usage & Resolution